MeiraGTx Holdings PLC (NASDAQ:MGTX – Get Free Report) CFO Richard Giroux sold 56,000 shares of MeiraGTx stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $12.51, for a total transaction of $700,560.00. Following the transaction, the chief financial officer directly owned 908,530 shares in the company, valued at $11,365,710.30. The trade was a 5.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
MeiraGTx Stock Down 3.1%
NASDAQ MGTX traded down $0.39 during trading on Tuesday, reaching $11.91. 168,142 shares of the stock traded hands, compared to its average volume of 729,845. MeiraGTx Holdings PLC has a fifty-two week low of $6.62 and a fifty-two week high of $15.35. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -8.05 and a beta of 1.20. The stock’s 50-day moving average price is $11.27 and its 200 day moving average price is $9.35.
MeiraGTx (NASDAQ:MGTX – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.04. The firm had revenue of $0.29 million during the quarter, compared to the consensus estimate of $17.00 million. Analysts anticipate that MeiraGTx Holdings PLC will post -1.53 EPS for the current fiscal year.
Analyst Ratings Changes
Read Our Latest Research Report on MGTX
Institutional Trading of MeiraGTx
A number of institutional investors have recently made changes to their positions in MGTX. BNP Paribas Financial Markets boosted its holdings in MeiraGTx by 43.8% during the second quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock worth $31,000 after purchasing an additional 1,466 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in MeiraGTx by 390.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,797 shares of the company’s stock valued at $57,000 after buying an additional 7,005 shares during the last quarter. ProShare Advisors LLC bought a new stake in MeiraGTx during the 4th quarter worth about $94,000. Abel Hall LLC bought a new stake in MeiraGTx during the 4th quarter worth about $98,000. Finally, Bank of Nova Scotia acquired a new position in shares of MeiraGTx during the 1st quarter worth about $105,000. Institutional investors own 67.48% of the company’s stock.
MeiraGTx Company Profile
MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.
The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.
Read More
- Five stocks we like better than MeiraGTx
- Is the Market Mispricing ServiceNow’s AI Future?
- Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus
- Amkor Sells Off After Earnings—Why Weak Guidance Isn’t the Real Story
- 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys?
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
